Prescient Therapeutics Ltd has released a press release.
Appendix 4D and Half Year Financial Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- December 2025 Quarterly Update and Appendix 4C
- PTX secures EU Authorisation to commence PTX-100 Trial
- PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
- September Quarterly Updated and Appendix 4C
- Appendix 4E and 2025 Annual Report
Later from Prescient Therapeutics
- March 2026 Quarterly Update and Appendix 4C
- June 2026 Quarterly Update and Appendix 4C
- Appendix 4E and 2026 Annual Report
- Prescient Therapeutics Opens SPP to Raise $7m Today
- PTX-100 CTCL Phase 2a study reaches review milestone
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics